{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:04:47Z","timestamp":1762459487234,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T00:00:00Z","timestamp":1533168000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"NIH\/NCI","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}]},{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.bbmt.2017.04.027","type":"journal-article","created":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T13:16:16Z","timestamp":1494249376000},"page":"1405-1410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation"],"prefix":"10.1016","volume":"23","author":[{"given":"Maria R.","family":"Khouri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias J.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison M.","family":"Gulbis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Turturro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celina","family":"Ledesma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Korbling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry I.","family":"Samuels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin M.","family":"Alousi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan O.","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Marin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krina K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uday R.","family":"Popat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos E.","family":"Bueso-Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Roland L.","family":"Bassett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issa F.","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2017.04.027_bib0010","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2007.06591.x","article-title":"Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia","volume":"137","author":"Khouri","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.04.027_bib0015","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2007.15.4757","article-title":"Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"26","author":"Sorror","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.04.027_bib0020","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1002\/cncr.26091","article-title":"Nonmyeloablative allogeneic stem cell transplantation in relapsed\/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors and effect of human leukocyte histocompatibility antigen subtype on outcome","volume":"117","author":"Khouri","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2017.04.027_bib0025","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/leu.2012.228","article-title":"Long term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome","volume":"27","author":"Brown","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.04.027_bib0030","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1182\/blood-2014-07-587519","article-title":"BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia\/lymphoma: reduced myelosuppression and GVHD","volume":"124","author":"Khouri","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.04.027_bib0035","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3109\/10428194.2014.930848","article-title":"Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis","volume":"56","author":"Poon","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2017.04.027_bib0040","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood-2010-03-275420","article-title":"Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial","volume":"116","author":"Dreger","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.04.027_bib0045","series-title":"Blood","article-title":"BFR (bendamustine, fludarabine, rituximab) vs. FCR nonmyeloablative allogeneic conditioning in relapsed\/refractory chronic lymphocytic leukemia (CLL): outcome results including minimal residual disease analysis","author":"Khouri","year":"2013122"},{"key":"10.1016\/j.bbmt.2017.04.027_bib0050","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/bmt.2014.227","article-title":"A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent","volume":"50","author":"Scarisbrick","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.04.027_bib0055","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","article-title":"Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"111","author":"Ferrajoli","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.04.027_bib0060","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2010.29.8133","article-title":"Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia","volume":"29","author":"Chen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.04.027_bib0065","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2011-03-339077","article-title":"Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia","volume":"118","author":"Badoux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.04.027_bib0070","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1182\/blood-2012-12-470005","article-title":"Long-term repair of T-cell synapse activity in a phase 2 trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)","volume":"121","author":"Shanafelt","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.04.027_bib0075","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1182\/blood-2010-04-278432","article-title":"The immunostimulatory effect of lenalidomide on NK cell function is profoundly inhibited by concurrent dexamethasone therapy","volume":"117","author":"Hsu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.04.027_bib0080","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2017.04.027_bib0095","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.04.027_bib0085","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2011-04-348292","article-title":"Lenalidomide maintenance following non-myeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 trial","volume":"118","author":"Kneppers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.04.027_bib0090","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.exphem.2012.10.004","article-title":"Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: results from a phase I\/II dose-finding study","volume":"41","author":"Wolschke","year":"2013","journal-title":"Exp Hematol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117304457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117304457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:59:37Z","timestamp":1761058777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879117304457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1083879117304457"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.04.027","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}